{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-25-003727","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.407962+00:00","generated_at":"2026-05-25T18:28:23.518520+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Alzamend Neuro amends bylaws to lower stockholder quorum to 35%, creates Series C Preferred Stock","bullets":["Board reduced quorum for stockholder meetings from majority of outstanding shares to 35%.","Filed Certificate of Designation for Series C Convertible Preferred Stock with Delaware.","Series C issuance part of previously disclosed exchange and purchase agreement with a sophisticated investor.","Exchange of 97.7511 shares of Series A for Series C; up to 500 additional Series C shares to be sold."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-25-003727","json":"https://secwatch.observer/filing/0001214659-25-003727.json","markdown":"https://secwatch.observer/filing/0001214659-25-003727.md","text":"https://secwatch.observer/filing/0001214659-25-003727.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465925003727/0001214659-25-003727-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465925003727/p312508k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T18:28:23.518520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}